Ann: Acrux presents at BioTrinity-ACR.AX, page-17

MW, understand your view on the lack of objectivity in analysts research and actually that is exacerbated in the current climate by their not wanting to be too assertive in their views, but do your own research and crunch the numbers. 3 quarters published and with our being half way through Q4 you can better estimate the fx rate to translate Q4 sales. (See my post under Q1 results for my crunching on this last month).

Analysts who get it so wrong with a positive recommendation followed by administration invariably get a poor reputation and a new job....

There will be a time to sell your rem shares, but that time is not now.

Wazz